The product fails independent testing anywhere from 10 percent of the time at the clean end to well over 40 percent in the largest sample, theres no completed long-term safety picture even for the pharmaceutical-grade version, and the entire risk-management apparatus is a certificate of analysis posted by the people selling it
Key Research Features Triple-hormone receptor agonist GIP + GLP-1 + Glucagon (GCGR) Tuned potency hierarchy across all three receptor targets C20 fatty diacid moiety albumin binding, ~6-day half-life in research models Simultaneous energy intake and energy expenditure pathway modeling 99% HPLC-verified purity LC-MS sequence and molecular weight identity confirmed Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, Retatrutide should be: Stored at 20C in a tightly sealed container Protected from light and moisture Reconstituted in sterile or bacteriostatic water Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information Currently an Investigational New Drug (IND) under active Phase 3 clinical investigation (TRIUMPH and TRANSCEND trial series) Not FDA-approved for any therapeutic indication as of current date Prohibited by the World Anti-Doping Agency (WADA) under S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics Supplied strictly as a Research Use Only (RUO) material Why Choose Summit Pep Labs
Lake at UTHealth Houston
Taking them together would significantly increase the risk of side effects without additional benefit
The news is overwhelmingly positive
Silverii GA, Marinelli C, Bettarini C, Del Vescovo GG, Monami M, Mannucci E
